New hope for young cancer patients: drug may fix Chemo-Related low platelets
NCT ID NCT07043894
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called romiplostim N01 in children, adolescents, and young adults (ages 6-24) with cancer who develop low platelet counts from chemotherapy. The drug is given as a weekly shot to help the body produce more platelets. The goal is to see if it can safely and quickly bring platelet levels back up, which could reduce bleeding risks and help patients complete their cancer treatment. The study involves 50 participants and will monitor for side effects like blood clots.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- romiplostim N01 (a platelet-boosting drug)
- What this could lead to
- If it works, this could offer a safe and effective way to quickly restore platelet counts in young cancer patients, reducing bleeding risks and allowing chemotherapy to continue on schedule.
- What could go wrong
- This is a small, early-phase (Phase 2) study with no comparison group, so results may not be definitive. The drug may not work for everyone and could cause side effects like blood clots or increased bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADOLESCENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Hidden heart risks in Wilson's disease: a new scan could spot them early
- Can a Tumor's DNA guide better cancer care for kids?
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug outperform standard care for a rare liver disease in teens?